stock-mb-logo-androidstock-mb-logo-ios
Stock Screener App
Free - Play StoreApp Store
InstallInstall
logo
Lineage Cell Therapeutics IncLCTX
$0.795113.07%-0.1195

Lineage Cell Therapeutics Inc (LCTX)

Lineage Cell Therapeutics Inc stock is traded at $0.7951, with a volume of 12,751,386. It is down -13.07% in the last 24 hours and down -18.73% over the past month. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapies for the treatment of degenerative diseases in the United States and internationally. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also develops Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy; ReGlyde, a HyStem product in preclinical development as a device for viscosupplementation, and as a platform for intraarticular drug delivery in osteoarthritis; and Premvia, a Hystem Hydrogel product, as well as develop bone grafting products for the orthopedic diseases and injuries. In addition, it markets GeneCards, a human gene database; MalaCards, a human disease database; and Hextend, a plasma volume expander used to treat or prevent hypovolemia, including albumin, generic 6% hetastarch solutions, and crystalloid solutions, as well as undertakes various research programs for vision restoration and Demyelination. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Previous Close:
$0.9146
Open:
$0.94
24h Volume:
12,751,386
Relative Volume:
5.04
Market Cap:
$201.12M
Revenue:
$14.78M
Net Income/Loss:
-$64.01M
P/E Ratio:
-
EPS:
-$0.2873
Net Cash Flow:
-$22.59M
1W Performance:
-26.38%
1M Performance:
-18.73%
6M Performance:
-36.39%
1Y Performance:
-57.71%
1-Day Range:
$0.77$0.95
1-Week Range:
$0.77$1.13
52-Week Range:
$0.77$1.99

Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile

Name
Lineage Cell Therapeutics Inc
Phone
510-871-4188
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA
Employee
77
Next Earnings Date
-
Latest SEC Filings
SEC
LCTX's Discussions on X
X

 

Market Cap

 

Revenue

 

Net Income

 

Cash Flow

 

EPS

 

Lineage Cell Therapeutics Inc Stock (LCTX) Financials Data

Similar to LCTX